Home
Clinical Trials
Sinupret Extract Coated Table...

Sinupret Extract Coated Tablets in Chronic Rhinosinusitis

Last Updated: 2018-02-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

572 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-04-28

Study Completion Date

2017-08-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the efficacy of the herbal medicinal product Sinupret extract versus placebo in the treatment of chronic rhinosinusitis (CRS) in adults.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis

NCT01146860

Acute Rhinosinusitis

COMPLETED PHASE3

Efficacy and Safety of Sinusitis Hevert SL Tablets Compared to Placebo in Adult Patients With Acute, Uncomplicated Rhinosinusitis

NCT02296814

Acute Rhinosinusitis

COMPLETED PHASE4

Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis

NCT01706484

Chronic Sinusitis

COMPLETED PHASE3

Trial With Bronchipret and Sinupret to Evaluate Acceleration of Mucociliary Clearance (MCC)

NCT01928901

Current Smokers

COMPLETED PHASE2

Anti-Inflammatory Agent in Sinusitis

NCT02874144

Nasal Polyps

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of the present double-blind, placebo-controlled, parallel-group, randomized, phase III clinical trial is to assess the efficacy, safety, and tolerability of Sinupret extract (3 x 160 mg = 480 mg daily) taken for up to 16-weeks compared with placebo in the treatment of chronic rhinosinusitis (CRS) in adults. In addition, in an exploratory approach to identify potential pharmacological modes of action underlying the expected treatment benefit, the anti-inflammatory activity of Sinupret extract will be assessed in a subset of CRS patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Rhinosinusitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Sinupret extract coated tablets

Sinupret extract coated tablets: one tablet three times a day orally during the 16-week treatment phase.

There will be no dose change during the trial.

Group Type EXPERIMENTAL

Sinupret extract coated tablets

Intervention Type DRUG

1 coated tablet 3 times a day for 16-weeks (1-1-1)

Placebo coated tablets

Placebo coated tablets: One tablet three times a day orally during the 16-week treatment Phase.

Group Type PLACEBO_COMPARATOR

Placebo coated tablets

Intervention Type DRUG

1 coated tablet 3 times a day for 16-weeks (1-1-1)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sinupret extract coated tablets

1 coated tablet 3 times a day for 16-weeks (1-1-1)

Intervention Type DRUG

Placebo coated tablets

1 coated tablet 3 times a day for 16-weeks (1-1-1)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Sinupret extract Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent (IC) including data protection declaration
2. Male and female outpatients aged ≥18 and ≤75 years

Women will be considered for inclusion if they are not pregnant (as confirmed by urine pregnancy test at V1 and V2), not breastfeeding, or if they are surgically sterile (have had a documented bilateral oophorectomy and/or hysterectomy) or if menopause is ensured (at least 12 months without menstrual bleeding). Women of childbearing potential must use a highly effective (failure rate less than 1% per year, i.e. Pearl Index \<1) method of contraception 2 weeks prior to trial inclusion and during the screening/treatment period of the clinical trial (e.g. vasectomized partner, sexual abstinence - the lifestyle of the female has to be such that there is complete abstinence from intercourse from 2 weeks prior to the first dose of trial medication until at least 72 hours after treatment - implants, injectables, combined oral contraceptives, or hormonal intrauterine devices).
3. Diagnosis of bilateral CRS without nasal polyps confirmed by:

* Nasal endoscopy during the screening phase to confirm inflammation, mucopurulent discharge, and/or edema/mucosal obstruction primarily in middle meatus without nasal polyps being present
* At the discretion of the investigator, results from a historic imaging diagnostic, i.e. computer tomography (CT), digital volume tomography (DVT), or magnetic resonance tomography (MRT) (before screening and not older than 24 months, not taken during acute exacerbation), which will be considered additionally for confirmation of bilateral involvement of middle meatus and paranasal sinuses without resolution of symptoms (mucosal changes within the ostiomeatal complex and/or sinuses)
4. Bilateral CRS characterized by:

* Presence of CRS symptoms for \>52 weeks prior to enrolment (V1) as documented in the medical file of the patient
* Major Symptom Score (MSS) ≥10 at V1 and V2 as assessed by the investigator (MSS INV), and rhinorrhea (anterior or posterior) and pain (facial pain or headache) each of at least moderate intensity (score ≥2)

Exclusion Criteria

1. Sinus surgery within the last 2 years (solitary sinus puncture is allowed)
2. Inferior turbinate reduction (by surgery or other methods) within the last 3 months
3. Presence or history of uni- or bilateral nasal polyps
4. Moderate to severe co-morbid asthma, including allergic asthma
5. Cystic fibrosis
6. Perennial (e.g. patients with clinical symptoms of allergic rhinitis against house dust/mite antigen) or seasonal allergic rhinitis
7. Rhinitis medicamentosa (drug induced rhinitis)
8. Aspirin-exacerbated respiratory disease (aspirin sensitivity)
9. Dentogenic sinusitis or otherwise unilateral sinusitis
10. Presence of anatomical deviations of the nasal septum that significantly impair nasal and paranasal ventilation/airflow
11. Known hypersensitivity to trial medication or excipients
12. Rare hereditary problems of fructose intolerance, galactose intolerance, lactase deficiency, glucose-galactose malabsorption, or sucrase- isomaltase insufficiency
13. Signs or symptoms of acute bacterial sinusitis (e.g. fever \>38.5°C, orbital complications, severe unilateral frontal headache, or toothache)
14. Treatment with antihistamines within 4 weeks prior to V1
15. Treatment with 2-3.5% hypertonic saline solution within 2 weeks prior to V1
16. Treatment with systemic or nasal antibiotics or corticosteroids within 4 weeks prior to V1
17. Treatment with decongestant preparations (α-sympathomimetics), analgesics (including systemic non-steroidal inflammatory drugs \[NSAIDs\], including paracetamol), mucolytics/secretolytics, or alternative medicine preparations for treatment of common cold-like symptoms or with immunomodulating properties within 7 days prior to V1
18. Peptic ulcer
19. Gastritis
20. Other diseases within 5 years prior to V1 that, in the opinion of the investigator, disqualifies the patient for trial enrolment (e.g. liver or kidney disease, severe somatopathic, neurological and/or psychiatric diseases, history of malignancy, alcohol or drug abuse, or immunodeficiency)
21. Parallel participation in another clinical trial, participation in a different trial within less than 6 weeks prior to trial entry, or previous randomization into this clinical trial
22. Known to be, or suspected of being unable to comply with the clinical trial protocol (CTP) that in the opinion of the investigator disqualifies the patient for trial enrolment (e.g. no permanent address, known to be non-compliant, or presenting an unstable psychiatric history)
23. Legal incapacity and/or other circumstances rendering the patient unable to understand the nature, scope, and possible impact of the clinical trial
24. Patients in custody by juridical or official order
25. Patients who have difficulties in understanding the local language in which the patient information (PI) is given
26. Patients who are members of the staff of the investigational site, staff of the sponsor or involved CRO, the investigator him/herself or close relatives

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers